Ovarielles Überstimulationssyndrom
Tóm tắt
Từ khóa
Tài liệu tham khảo
Abramov Y, Schenker JG, Lewin A et al. (2001) Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndome. Fertil Steril 76(1): 51–57
Alvarez C, Martí-Bonmatí L, Novella-Maestre E et al. (2007) Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92(8): 2931–2937
Artini PG, Monti M, Fasciani A et al. (2002) Vascular endothelial growth factor, interleukin-6 and interleukin-2 in serum and follicular fluid of patients with ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 101(2): 169–174
Bellver J, Muñoz EA, Ballesteros A et al. (2003) Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod 18: 2283–2288
Ben-Chetrit A, Eldar-Geva T, Gal M et al. (2001) The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod 16: 1880–1884
Binder H, Cupisti S, Dittrich R et al. (2004) Ovarielles Überstimulationssyndrom – update Teil 2. Geburtsh Frauenheilkd 64: R77–R100
Binder H, Dittrich R, Einhaus F et al. (2007) Update on ovarian hyperstimulation syndrome: part 1 – incidence and pathogenesis. Int J Fert Womens Med 52(1): 251–255
Binder H, Dittrich R, Einhaus F et al. (2007) Update on ovarian hyperstimulation syndrome: part 2 – clinical signs and treatment. Int J Fert Womens Med 52(2) (in press)
Binder H, Dittrich R, Hager I et al. (2007) Association of FSHR and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome (OHSS). Reproduction (in press)
Binder H, Flegel WA, Emran J et al. (2007) Blood group A may be an independent risk factor for the ovarian hyperstimulation syndrome (OHSS). Transfusion Medicine (submitted)
Chang AS, Odem RR, Ratts VS (2003) Addition of Metformin with gonadotropin stimulation in PCOS patients. Fertil Steril 80 (Suppl 3): S110–111
d’Alva CB, Serafini P, Motta E et al. (2005) Absence of follicle-stimulating hormone receptor activating mutations in women with iatrogenic ovarian hyperstimulation syndrome. Fertil Steril 83: 1695–1699
Daelemans C, Smits G, de Maertelaer V et al. (2004) Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. J Clin Endocrinol Metab 89: 6310–6315
Delbaere A, Smits G, Olatunbosun O et al. (2004) New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Hum Reprod 2004; Advance Access, DOI:10.1093/humrep/deh124,1-4
Delbaere A, Smits G, Vassart G, Costagliola S (2006) Genetic predictors of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Nat Clin Pract 2(11): 590–591
Delvigne A, Rozenberg S (2003) Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 9: 77–96
Di Carlo C, Bruno P, Cirillo D et al. (1997) Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome. Hum Reprod 12: 2115–2117
Enskog A, Henriksson M, Unander M et al. (1999) Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 71(5): 808–814
Fan QR, Hendrickson WA (2007) Assembly and structural characterization of an authentic complex between human follicle stimulating hormone and a hormone-binding ectodomain of its receptor. Mol Cell Endocrinol 260–262: 73–82
Fan QR, Hendrickson WA (2005) Structure of human follicle-stimulating hormone in complex with its receptor. Nature 433: 269–277
Foong LC, Bhagavath B, Kumar J, Ng SC (2002) Ovarian hyperstimulation syndrome is associated with reversible impairment of vascular reactivity. Fertil Steril 78(6): 1159–1163
Geisthövel F, Christ L, Haibt L, Ochsner A (2003) Assisted reproductive techniques: risks, contraindications, prognostic factors, therapeutic strategies. Andrologia 35(3): 168–169
Gokmen O, Ugur M, Ekin M et al. (2001) Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol 96(2): 187–192
Golan A, Ron-el R, Herman R et al. (1989) Ovarian hyperstimulation syndrome an update review Obst Gynecol Surv 44: 430–440
Gromoll J, Ried T, Holtgreve-Grez H et al. (1994) Localization of the human FSH receptor to chromosome 2p21 using a genomic probe comprising exon 10. J Molec Endocrinol 12: 265–271
Haimov-Kochman R, Yanai N, Yagel S et al. (2004) Spontaneous ovarian hyperstimulation syndrome and HL are entities in continuum. Ultrasound Obstet Gynecol 24: 675–678
Hammadeh ME, Fischer-Hammadeh C, Hofmeister H et al. (2003) Fibroblast growth factor (FGF), intracellular adhesion molecule (sICAM-1) level in serum and follicular fluid of infertile women with polycystic ovarian syndrome, endometriosis and tubal damage, and their efect on ICSI outcome AJRI 50: 124–130
Heckert LL, Daley IJ, Griswold MD (1992) Structural organization of the follicle-stimulating hormone receptor gene. Mol Endocrinol 6: 70–80
Ito M, Harada T, Iwabe T, Tanikawa M, Terakawa N (2000) Cytokine levels in a patient with severe ovarian hyperstimulation syndrome before and after the ultrafiltration and reinfusion of ascitic fluid. J Ass Reprod Gen 17(2): 118–120
Jäger W, Diedrich K, Wild L (1987) Elevated levels of CA 125 in serum of patients suffering from ovarian overstimulation syndrome. Fertil Steril 48: 675–678
Kahraman S, Yakin K, Vanlioglu F et al. (2003) Metformin as an adjuvant therapy in patients with polycystic ovaries undergoing controlled ovarian stimulation. Hum Reprod 18: 40xviii–42xviii, 115
Kaiser UB (2003) The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 349(8): 729–732
Keck C, Neulen J, Behre HM, Breckwoldt M (2002) Endokrinologie, Reproduktionsmedizin, Andrologie, 2. Aufl. Thieme, Stuttgart
Kerkela E, Skottman H, Friden B et al. (2007) Exclusion of coding-region mutations in luteinizing hormone and follicle-stimulating hormone receptor genes as the cause of ovarian hyperstimulation syndrome. Fertil Steril 87: 603–606
Kissler S, Siebzehnrübl E, Kaufmann M (2002) Von der Pathophysiologie und Prävention des ovariellen Überstimulationssyndroms (OHSS) bis zur stadiengerechten Therapie. Geb Fra 62: 1155–1161
Kol S (2004) Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 81(1): 1–5
Kol S (2003) Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent! Hum Reprod 18: 1557–1558
Levinsohn-Tavor O, Friedler S, Schachter M et al. (2003) Coasting – what is the best formula? Hum Reprod 18: 937–940
Ludwig M, Diedrich K (2001) Evaluation of an optimal luteal phase support protocol in IVF. Acta Obstet Gynecol Scand 80(5): 452–466
Ludwig M, Gembruch U, Bauer O, Diedrich K (1998) Ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS. Hum Reprod 13(8): 2082–2087
Ludwig M, Bauer O, Lopens A et al. (1998) Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome. Hum Reprod 13: 30–32
Ludwig M, Doody KJ, Doody KM (2003) Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 79(5): 1051–1059
Lyons CA, Wheeler CA, Frishman GN et al. (1994) Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors Hum Reprod 9: 792–799
Mathur R, Hayman G, Bansal A, Jenkins J (2002) Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception. Fertil Steril 78(6): 1154–1158
McElhinney B, Ardill J, Caldwell C et al. (2002) Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others? Hum Reprod 17: 1548–1553
McGowan BMC, Kay LA, Perry DJ (2003) Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization an a woman heterozygous for the pothrombin 3‘ UTR and factor V Leiden mutations. Am J Hematol 73: 276–278
Ogawa S, Minakami H, ArakiI S et al. (2001) PHYSIOLOGY: a rise of the serum level of von Willebrand factor occurs before clinical manifestation of the severe form of ovarian hyperstimulation syndrome. J Ass Reprod Gen 18(2): 114–119
Orvieto R (2003) Prediction of ovarian hyperstimulation syndrome: challenging the estradiol mythos. Hum Reprod 18: 665–667
Rizk B (2006) Ovarian hyperstimulation syndrome: epidemiology, pathophysiology, prevention and management. Cambridge University Press, New York
Smits G, Olatunbosun O, Delbaere A et al. (2003) Brief report: ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 349: 760–766
Stewart JA, Hamilton PJ, Murdoch AP (1997) Upper limb thrombosis associated with assisted conception treatment. Hum Reprod 12: 2174–2175
Stewart JA, Hamilton PJ, Murdoch AP (1997) Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 12: 2167–2173
Thomas K, Searle T, Quinn A et al. (2002) The value of routine estradiol monitoring in assisted conception cycles. Acta Obstet Gynecol Scand 81(6): 551–554
Tozer AJ, Iles RK, Iammarrone E et al. (2004) The effects of „coasting“ on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Hum Reprod 19(3): 522–528
Ujioka T, Matsuura K, Tanaka N, Okamura H (1998) Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model. Hum Reprod 13: 3009–3015
Ulug U, Aksoy E, Erden H et al. (2003) Bilateral internal jugular venous thrombosis following successful assisted conception in the absence of ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 109(2): 231–233
Vanky E, Kjørød SB, Maesel A et al. (2004) Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome. Fertil Steril 81(2): 459–462
Vanlioglu F, Kahraman S, Karlikaya G et al. (2003) Effect of metformin on subgroups pf patients with polycystic ovaries undergoing controlled ovarian stimulation for assisted reproduction. Fertil Steril 80 (Suppl. 3): S111
Vasseur C, Rodien P, Beau I et al. (2003) Brief report: a chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 349: 753–759
Wang TH, Horng SG, Chang CL et al. (2002) Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 87: 3300–3308
Yarali H, Yildiz BO, Demirol A et al. (2002) Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 17: 289–294
Griesinger G, Diedrich K, Tarlatzis B, Kolibianakis EM (2006) GnRH-antagonists in ovarian stimulation for IVF in patients with [1] poor response to gonadotrophins, [2] polycystic ovary syndrome, and [3] risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13(5): 628–638
Griesinger G, von Otte S, Schroer A et al. (2007) Elective cryopreservation of all pronuclear oocytes after GnRH-agonist triggering of final oocyte maturation in OHSS risk patients: a prospective, observational proof-of-concept study. Hum Reprod 22(5): 1348–1352